RNA结合蛋白在甲状腺癌发病机制中作用的研究进展

doi:10.16352/j.issn.1001-6325.2022.08.1306

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (8): 1306-1309.doi: 10.16352/j.issn.1001-6325.2022.08.1306

RNA结合蛋白在甲状腺癌发病机制中作用的研究进展

周美岑^*, 兰玲, 邓微

北京大学第四临床医学院北京积水潭医院内分泌科,北京 100035

收稿日期:2021-01-04 修回日期:2021-07-19 出版日期:2022-08-05 发布日期:2022-08-01
通讯作者: ^*zhoumeicen@126.com
基金资助:
北京积水潭医院院内青年基金(QN-201921); 北京积水潭医院自然基金培育计划(ZR-2021115)

Advances of research on the function of RNA binding proteins in the pathogenesis of thyroid carcinoma

ZHOU Mei-cen^*, LAN Ling, DENG Wei

1. Department of Endocrinology, Beijing Jishuitan Hospital, the Fourth Clinical College of Peking University, Beijing 100035, China

Received:2021-01-04 Revised:2021-07-19 Online:2022-08-05 Published:2022-08-01
Contact: ^*zhoumeicen@126.com

摘要/Abstract

摘要： RNA结合蛋白(RBP)在甲状腺癌的发病进程中发挥重要作用,其可在转录后水平或翻译水平上调节肿瘤相关基因mRNA的转录、核输出、选择性剪切及翻译等细胞内活动,进而调控甲状腺癌细胞的增殖、凋亡和迁移等,发挥促进或抑制肿瘤发生的作用。临床上一系列RBP分子与甲状腺癌患者的分型和预后呈显著相关性,具有指导甲状腺癌分型以及预测其治疗预后的作用。

关键词: RNA结合蛋白, 甲状腺癌, 肿瘤生长

Abstract: RNA-binding protein (RBP) plays an important role in the pathogenesis of thyroid cancer. It can regulate the intracellular activities such as transcription, nuclear output, alternative splicing and translation of mRNA from tumor-related genes at the post-transcriptional or translation levels, and then regulate the proliferation, apoptosis and migration of thyroid cancer, thereby promoting or inhibiting the occurrence of tumors. Clinically, a series of RBP molecules are significantly correlated with the classification and prognosis of patients with thyroid cancer and may support the oncological classification, evaluation and prediction of prognosis of thyroid cancer.

Key words: RNA-binding protein, thyroid carcinoma, tumor growth

中图分类号:

R737.9

周美岑, 兰玲, 邓微. RNA结合蛋白在甲状腺癌发病机制中作用的研究进展[J]. 基础医学与临床, 2022, 42(8): 1306-1309.

ZHOU Mei-cen, LAN Ling, DENG Wei. Advances of research on the function of RNA binding proteins in the pathogenesis of thyroid carcinoma[J]. Basic & Clinical Medicine, 2022, 42(8): 1306-1309.

参考文献 25

[1]	Castello A, Fischer B, Eichelbaum K, et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins[J]. Cell, 2012,49:1393-1406.
[2]	Jonas K, Calin GA, Pichler M.RNA-binding proteins as important regulators of long non-coding RNAs in cancer[J].Int J Mol Sci, 2020,21:2969.doi:10.3390/ijms21082969.
[3]	Wu M, Tong CWS, Yan W, et al. The RNA binding protein HuR:a promising drug target for anticancer therapy[J]. Curr Cancer Drug Targets, 2019,19:382-399.
[4]	Du LB,Li RH, Ge MH,et al. Incidence and mortality of thyroid cancer in China, 2008—2012[J]. Chin J Cancer Res,2019,31:144-151.
[5]	Allegri L, Mio C, Russo D, et al. Efects of HuR downregulation on anaplastic thyroid cancer cells[J]. Oncol let, 2018, 15:575-579.
[6]	Wang Y, He H, Liyanarachchi S, et al. The role of SMAD3 in the genetic predisposition to papillary thyroid carcinoma[J]. Genet Med,2018, 20:927-935.
[7]	Zhang MP, Zhang WS, Tan J, et al. Poly r(C) binding protein (PCBP) 1 expression is regulated by the E3 ligase UBE4A in thyroid carcinoma[J]. Biosci Rep,2017, 37.doi:10.1042/BSR20170114.
[8]	Giaginis C, Alexandrou P, Delladetsima I, et al. Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions[J]. Pathol Oncol Res, 2016, 22:189-196.
[9]	Allegri L, Baldan F, Roy S. The HuR CMLD-2 inhibitor exhibits antitumor effects via MAD2 downregulation in thyroid cancer cells[J]. Sci Rep, 2019,9:7374.doi:10.1038/s41598-019-43894-0.
[10]	Allegri L, Mio C, Russo D, et al. Effects of HuR downregulation on anaplastic thyroid cancer cells[J]. Oncol Lett, 2018,15:575-579.
[11]	Trojanowicz B, Brodauf L, Sekulla C,et al. The role of AUF1 in thyroid carcinoma progression[J]. Endocr Relat Cancer,2009,16:857-871.
[12]	Trojanowicz B, Sekulla C, Dralle H, et al.Expression of ARE-binding proteins AUF1 and HuR in follicular adenoma and carcinoma of thyroid gland[J]. Neoplasma,2016;63:371-377.
[13]	Donati B, Ciarrocchi A. Telomerase and telomeres biology in thyroid cancer[J]. Int J Mol Sci, 2019, 20:2887.doi:10.3390/ijms20122887.
[14]	Yuan XT, Catharina L, Xu DW. Mechanisms underlying the activation of TERT transcription and telomer-ase activity in human cancer:old actors and new players[J]. Oncogene, 2019,38:6172-6183.
[15]	Colebatch JA, Dobrovic A, Cooper AW. TERT gene:its function and dysregulation in cancer[J]. J Clin Pathol, 2019, 72:281-284.
[16]	Jin AQ, Xu JH, Wang Y. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer[J]. Medicine (Baltimore), 2018,97:e11548,doi:10.1097/MD,0000000000011548.
[17]	Panebianco F, Nikitski AV, Nikiforova MN,et al. Spec-trum of TERT promoter mutations and mechanisms of activation in thyroid cancer[J]. Cancer, 2019,8:5831-5839.
[18]	Chung JH.BRAF and TERT promoter mutations:clinical application in thyroid cancer[J].Endocr J, 2020,67:577-584.
[19]	Chara C, Sarah B. The La-related proteins, a family with connections to cancer[J]. Biomolecules, 2015,5:2701-2722.
[20]	Sui XM, Sui YN, Wang YH. LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway[J]. Mol Med Rep,2018,17:7521-7528.
[21]	Zhang XT, Di CX, Chen YH,et al. Multilevel regulation and molecular mechanism of poly (rC)-binding protein 1 in cancer[J]. FASEB J, 2020. doi:10.1096/fj.202000911R.
[22]	Guo J, Jia R.Splicing factor poly(rC)-binding protein 1 is a novel and distinctive tumor suppressor[J]. J Cell Physiol, 2018,234:33-41.
[23]	Zhang X, Di C, Chen Y, et al. Multilevel regulation and molecular mechanism of poly (rC)-binding protein 1 in cancer[J].FASEB J, 2020,34:15647-15658.
[24]	Wang YQ, He HL, Liyanarachchi S,et al. The role of SMAD3 in the genetic predisposition to papillary thyroid carcinoma[J]. Genet Med, 2018,20:927-935.
[25]	Gulius J, Gudmar T, Kjons S,et al. A genome-wide association study yields five novel thyroid cancer risk loci[J]. Nat Commun, 2017,14,8:14517. doi:10.1038/ncomms14517.

RNA结合蛋白在甲状腺癌发病机制中作用的研究进展

Advances of research on the function of RNA binding proteins in the pathogenesis of thyroid carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王继辉, 曹吉烈, 张立军, 张军, 鹿文葆. TARBP2降解AKAP12转录本促进人乳腺癌细胞转移[J]. 基础医学与临床, 2023, 43(8): 1259-1264.
[2]	赫佳音, 杨嘉宾, 陈仲扬, 马艳妮, 余佳. 烯醇化酶1通过影响mRNA定位调节人胚胎干细胞自我更新能力[J]. 基础医学与临床, 2023, 43(6): 867-874.
[3]	柳俊, 邹定峰, 缪时英, 宋伟, 李凯. 基因Cdca2敲除对小鼠精子发生和生育力无明显影响[J]. 基础医学与临床, 2023, 43(5): 717-723.
[4]	田艳, 马姣姣, 席雪华, 张波. 超声检查评估分化型甲状腺癌颈部转移淋巴结的研究进展[J]. 基础医学与临床, 2023, 43(3): 505-508.
[5]	陈施静, 傅菁岚, 邓媛媛, 张颖, 刘慧霞. 维生素D-24-羟化酶与甲状腺癌的相关性研究进展[J]. 基础医学与临床, 2023, 43(3): 490-494.
[6]	傅菁岚, 邓媛媛, 张颖, 章鑫煦, 陈施静, 刘慧霞. 甲状腺癌与糖尿病的相关性研究进展[J]. 基础医学与临床, 2022, 42(4): 667-670.
[7]	谢丽君, 朱高红, 赵继华, 张海波, 王娇. 甲状腺癌肿瘤干细胞的来源和存活途径[J]. 基础医学与临床, 2022, 42(2): 321-324.
[8]	刘浪, 王海存, 高欣, 刘广麟, 赵俞乔, 姜兴明. CircRNA锌指RNA结合蛋白在恶性肿瘤中作用研究进展[J]. 基础医学与临床, 2022, 42(10): 1585-1590.
[9]	李凯, 邙新雨, 邹定峰, 李梦真, 缪时英, 王琳芳, 宋伟. 全转录组测序分析精子发生中RNA结合蛋白质的动态表达[J]. 基础医学与临床, 2021, 41(6): 825-830.
[10]	刘亚琪, 郑承红. miR-205通过靶向调控Wnt-5a抑制乳头状甲状腺癌的细胞增殖[J]. 基础医学与临床, 2021, 41(3): 358-363.
[11]	傅松波, 马承旭, 井高静, 赵楠, 汤旭磊, 牟军勤, 常寅龙. 苦参碱对人乳头状甲状腺癌细胞系TPC-1增殖和迁移的影响[J]. 基础医学与临床, 2021, 41(12): 1730-1735.
[12]	曹邓晗, 陈奎生. miR-135b-3p调控XAF1表达影响甲状腺癌细胞的迁移、侵袭和放射增敏性[J]. 基础医学与临床, 2020, 40(6): 790-796.
[13]	曹邓晗, 陈奎生. miR-197-3p调控DMBT1抑制甲状腺癌细胞系增殖、迁移和侵袭[J]. 基础医学与临床, 2020, 40(5): 644-650.
[14]	张美莲, 王志星, 胡艳, 冉坤念, 韩为, 彭小忠. RNA结合蛋白作为氯福克酚药靶的机制初探[J]. 基础医学与临床, 2020, 40(5): 621-626.
[15]	张璐刘跃武. 雌激素与甲状腺癌的关系[J]. 基础医学与临床, 2010, 30(7): 782-784.